Cancer drug Keytruda, vaccines propel Merck to quarterly profit beat

Merck & Co Inc reported higher-than-expected second-quarter profit and revenue and raised its full-year earnings forecast on Tuesday, powered by strong demand for its blockbuster cancer immunotherapy Keytruda and vaccine sales.